Dutch researchers compared the use of vaginal brachytherapy (radiation therapy given internally, using implants) to external-beam radiation therapy (radiation given from a machine outside the body) to treat uterine cancer that has a higher risk of recurrence (cancer that comes back after treatment).
Results of a new study show that raloxifene (Evista) is associated with lowering the risk of developing uterine (endometrial) cancer by 50%. Raloxifene is a selective estrogen receptor modulator (SERM) used to treat osteoporosis (thinning of the bones) and may lower the risk of breast cancer.
